Drug Trial Radar · NCT05691478
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
1,122
Planned (sponsor's estimate)
Start
Mar 3, 2023
Primary completion
Mar 20, 2030
Study completion Mar 20, 2030
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma. Cabozantinib is in a class of medications called kinase inhibitors which block protein signals affecting new blood vessel formation and the ability to activate growth signaling pathways. This may help slow the growth of tumor cells. The drugs used in standard chemotherapy for this trial are methotrexate, doxorubicin, and cisplatin (MAP). Methotrexate stops cells from making DNA and may kill tumor cells. It is a type of antimetabolite. Doxorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of tumor cells in the body. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Adding cabozantinib to standard chemotherapy may work better in treating newly diagnosed osteosarcoma.
Conditions
- High Grade Osteosarcoma
- Localized Osteosarcoma
- Metastatic Osteosarcoma
- Secondary Osteosarcoma
Interventions
Bone ScanProcedure
Undergo bone scintography
Cabozantinib S-malateDrug
Given PO
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
Doxorubicin HydrochlorideDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
MethotrexateDrug
Given IV
Surgical ProcedureProcedure
Undergo surgery
X-Ray ImagingProcedure
Undergo X-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicity (Feasibility)Time frame: Baseline up to 6 weeks
- Event-free survival (EFS) (Phase II)Time frame: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
- EFS (Phase III)Time frame: From randomization until disease progression, relapse, diagnosis of a second malignant neoplasm, death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
- Overall survivalTime frame: From randomization until death or last contact, whichever occurs first, assessed up to 5 years after completion of study treatment
Locations
202 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Nicklaus Children's Hospital
Miami, Florida
Miami Cancer Institute
Miami, Florida
AdventHealth Orlando
Orlando, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Nemours Children's Clinic - Pensacola
Pensacola, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Showing 40 of 202 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.